Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

velpatasvir

- PMLiVE

Harvoni cleared for broader use in hepatitis C

Gilead Sciences’ drug wins US approval for use in liver transplant patients

- PMLiVE

Gilead’s John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

Gilead Sciences

Priority FDA review for new Gilead HCV combination therapy

Sovaldi/velpatasvir combination could be approved in the US by summer 2016

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

Research Partnership

Infographic: HCV LATAM

An introduction to the HCV LATAM patient.

Research Partnership

- PMLiVE

Pharma healthier than it appears, says report

Thomson Reuters research finds global pharma sales will hit $1.3trn by 2018

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

- PMLiVE

Access to new hep C treatments put under the spotlight

NICE plans to restrict use of BMS’ Daklinza follow funding delay for Gilead's Sovaldi

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links